Below are the financial statements of Guardant Health, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | — | — | — |
| Precision oncology testing | 687.94a | 514.25a | 392.05a |
| Development services and other | 51.08a | 49.7a | 57.49a |
| Total revenue | 739.02a | 563.95a | 449.54a |
| Costs and operating expenses | — | — | — |
| Cost of precision oncology testing | -260.58a | -205.53a | -148.2a |
| Cost of development services and other | -29.22a | -21.52a | -8.13a |
| Research and development expense | -347.75a | -367.19a | -373.81a |
| Sales and marketing expense | -364.94a | -295.23a | -299.83a |
| General and administrative expense | -180.12a | -155.8a | -163.96a |
| Other operating expense | 0a | -83.4a | 0a |
| Total costs and operating expenses | -1,182.61a | -1,128.67a | -993.92a |
| Loss from operations | -443.59a | -564.73a | -544.38a |
| Interest income | 53.69a | 35.37a | 6.07a |
| Interest expense | -2.58a | -2.58a | -2.58a |
| Other income (expense), net | -42.61a | 53.17a | -12.78a |
| Fair value adjustments of noncontrolling interest liability | 0a | 0a | -99.79a |
| Loss before provision for income taxes | -435.09a | -478.76a | -653.45a |
| Provision for income taxes | -1.28a | -0.69a | -1.14a |
| Net loss | -436.37a | -479.45a | -654.59a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Guardant Health’s data sources below and access millions more through our Disclosure Search.